ResMed Statistics
Total Valuation
ResMed has a market cap or net worth of $27.82 billion. The enterprise value is $28.75 billion.
Market Cap | 27.82B |
Enterprise Value | 28.75B |
Important Dates
The next estimated earnings date is Thursday, August 1, 2024, after market close.
Earnings Date | Aug 1, 2024 |
Ex-Dividend Date | May 8, 2024 |
Share Statistics
ResMed has 146.91 million shares outstanding. The number of shares has increased by 0.04% in one year.
Shares Outstanding | 146.91M |
Shares Change (YoY) | +0.04% |
Shares Change (QoQ) | -0.06% |
Owned by Insiders (%) | 0.77% |
Owned by Institutions (%) | 58.22% |
Float | 145.63M |
Valuation Ratios
The trailing PE ratio is 29.09 and the forward PE ratio is 22.22. ResMed's PEG ratio is 1.75.
PE Ratio | 29.09 |
Forward PE | 22.22 |
PS Ratio | 6.07 |
Forward PS | 5.64 |
PB Ratio | 6.01 |
P/FCF Ratio | 25.53 |
PEG Ratio | 1.75 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.75, with an EV/FCF ratio of 26.38.
EV / Earnings | 29.99 |
EV / Sales | 6.27 |
EV / EBITDA | 19.75 |
EV / EBIT | 23.21 |
EV / FCF | 26.38 |
Financial Position
The company has a current ratio of 3.04, with a Debt / Equity ratio of 0.25.
Current Ratio | 3.04 |
Quick Ratio | 1.32 |
Debt / Equity | 0.25 |
Debt / EBITDA | 0.80 |
Debt / FCF | 1.07 |
Interest Coverage | 22.63 |
Financial Efficiency
Return on equity (ROE) is 21.90% and return on invested capital (ROIC) is 16.95%.
Return on Equity (ROE) | 21.90% |
Return on Assets (ROA) | 14.10% |
Return on Capital (ROIC) | 16.95% |
Revenue Per Employee | $452,087 |
Profits Per Employee | $94,515 |
Employee Count | 10,140 |
Asset Turnover | 0.67 |
Inventory Turnover | 2.20 |
Taxes
In the past 12 months, ResMed has paid $225.49 million in taxes.
Income Tax | 225.49M |
Effective Tax Rate | 19.05% |
Stock Price Statistics
The stock price has decreased by -11.79% in the last 52 weeks. The beta is 0.69, so ResMed's price volatility has been lower than the market average.
Beta (5Y) | 0.69 |
52-Week Price Change | -11.79% |
50-Day Moving Average | 207.49 |
200-Day Moving Average | 177.97 |
Relative Strength Index (RSI) | 36.92 |
Average Volume (20 Days) | 1,315,534 |
Short Selling Information
The latest short interest is 8.24 million, so 5.61% of the outstanding shares have been sold short.
Short Interest | 8.24M |
Short Previous Month | 10.21M |
Short % of Shares Out | 5.61% |
Short % of Float | 5.66% |
Short Ratio (days to cover) | 10.05 |
Income Statement
In the last 12 months, ResMed had revenue of $4.58 billion and earned $958.38 million in profits. Earnings per share was $6.51.
Revenue | 4.58B |
Gross Profit | 2.56B |
Operating Income | 1.21B |
Pretax Income | 1.18B |
Net Income | 958.38M |
EBITDA | 1.46B |
EBIT | 1.24B |
Earnings Per Share (EPS) | $6.51 |
Balance Sheet
The company has $237.91 million in cash and $1.17 billion in debt, giving a net cash position of -$929.54 million or -$6.33 per share.
Cash & Cash Equivalents | 237.91M |
Total Debt | 1.17B |
Net Cash | -929.54M |
Net Cash Per Share | -$6.33 |
Equity (Book Value) | 4.63B |
Book Value Per Share | 31.52 |
Working Capital | 1.58B |
Cash Flow
In the last 12 months, operating cash flow was $1.20 billion and capital expenditures -$109.03 million, giving a free cash flow of $1.09 billion.
Operating Cash Flow | 1.20B |
Capital Expenditures | -109.03M |
Free Cash Flow | 1.09B |
FCF Per Share | $7.41 |
Margins
Gross margin is 55.78%, with operating and profit margins of 26.48% and 20.91%.
Gross Margin | 55.78% |
Operating Margin | 26.48% |
Pretax Margin | 25.83% |
Profit Margin | 20.91% |
EBITDA Margin | 31.75% |
EBIT Margin | 27.02% |
FCF Margin | 23.77% |
Dividends & Yields
This stock pays an annual dividend of $1.92, which amounts to a dividend yield of 1.01%.
Dividend Per Share | $1.92 |
Dividend Yield | 1.01% |
Dividend Growth (YoY) | 9.09% |
Years of Dividend Growth | 12 |
Payout Ratio | 29.49% |
Buyback Yield | -0.04% |
Shareholder Yield | 0.98% |
Earnings Yield | 3.45% |
FCF Yield | 3.92% |
Analyst Forecast
The average price target for ResMed is $213.67, which is 12.84% higher than the current price. The consensus rating is "Buy".
Price Target | $213.67 |
Price Target Difference | 12.84% |
Analyst Consensus | Buy |
Analyst Count | 12 |
Revenue Growth Forecast (5Y) | 8.45% |
EPS Growth Forecast (5Y) | 13.70% |
Stock Splits
The last stock split was on August 31, 2010. It was a forward split with a ratio of 2:1.
Last Split Date | Aug 31, 2010 |
Split Type | Forward |
Split Ratio | 2:1 |
Scores
ResMed has an Altman Z-Score of 10.17 and a Piotroski F-Score of 5.
Altman Z-Score | 10.17 |
Piotroski F-Score | 5 |